2003). On account of these defects, insulin therapy alone is unlikely to achieve ideal control and safety. In order to improve the glycemic control a dual hormone therapy may be needed. Today, glucagon is only used to treat severe insulin‐induced hypoglycemia in diabetes. The closed‐loop artificial pancreas, imitating normal physiology by administering either insulin or glucagon, demonstrates the feasibility of a safe blood glucose regulation in individuals with type 1 diabetes (Ward et al. 2008; El‐khatib et al. 2010; Haidar et al. 2013). The gene discussed is INS; the disease is type 1 diabetes mellitus.